Bumble Shares Surge 50% on $1 Billion Buyout Talks 
European Auto Stocks Rise as EU-China Trade Deal Targets Hybrid Imports 
Gold Prices Rebound as Dollar Weakens Ahead of US Inflation Data 
Trump Secures Russian Diesel Deal as US Fuel Prices Surge 
Coinbase CEO Backs SEC Accredited Investor Reform 
FAA Warns US Airlines Over Saudi Arabia Flight Risks 
Airbus Tests Valkyrie Combat Drone in Europe for Eurofighter Integration 
Apple Supplier Luxshare Faces US Patent Probe, Sees Limited Impact 
Meta Launches Muse Wonder AI Models, Shares Rise 3.7% 
Moonshot AI Executives Seek Settlement Ahead of Hong Kong IPO 
Asian Stocks Plunge as AI Chip Selloff Hits South Korea and Japan 
Samsung, SK Hynix Shares Fall as China's CXMT Advances DRAM Technology 
UK Finance Minister Healey Calls for Fiscal Discipline Amid Global Risks 
Visa Wins China Approval to Prepare Domestic Payments Expansion 
Ethereum Foundation-Linked Wallets Move $11.13M in ETH to Kraken 
US Dollar Near 18-Month High Ahead of Inflation Data 
Nasdaq Falls as Oil Prices Surge Ahead of Bank Earnings 
Add as a preferred source on Google
Samsung Biologics is now confirmed to produce Moderna’s COVID-19 vaccines in South Korea. The biotechnology company headquartered in Incheon is said to be working to hasten preparations and begin the production of the shots in the second half of this year.
Confirmation of the vaccine production deal
The Korea Herald reported that Samsung Biologics is preparing its drug manufacturing facility in Songdo, Incheon. This is said to be one of the largest in the world and it is here where the biotech firm will be handling the filling and finishing process of Moderna vaccine production. To be more specific, the mRNA-1273 which is the American pharmaceutical company’s messenger-RNA-based COVID-19 shot.
The Samsung and Moderna agreement was officially signed and this was witnessed by South Korean President Moon Jae In looking. The deal is actually part of the Korean-US vaccine partnership that was one of the agendas at the recent summit that was held in the U.S. last week.
The agreement between Samsung Biologics and Moderna
Samsung Biologics will be filling up vials and packaging them for sale and distribution. The main vaccine content will be coming directly from Moderna and Lonza, its Swiss production partner, and the overall finishing process will be done in Korea.
"This vaccine is paramount to people around the world in the fight against the COVID-19 pandemic, and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine," Samsung Biologics CEO, John Rim, said in a press release."Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021."
On the other hand, Moderna’s chief technical operations and quality officer, Juan Andres, said that they are pleased to team up with Samsung Biologics for the fill and finish production. He explained that this arrangement will help them continue to boost their manufacturing capacity outside of the U.S. as they remained committed to beating COVID-19.
Meanwhile, South Korean government officials gladly welcomed the partnership as this is a big opportunity for the country to scale up and be a global factory of vaccines for COVID-19.
